Nkarta Inc is a pioneering biopharmaceutical firm focused on the development of innovative cell therapies for cancer patients. With a keen eye on cellular immunotherapy, Nkarta harnesses chimeric antigen receptors to empower lymphocytes to detect and attack tumor cells. Its leading projects, NKX101 and NKX019, are trailblazing treatments targeting acute myeloid leukemia and B cell malignancies, respectively. Founded in 2015 and based in South San Francisco, California, Nkarta stands at the forefront of cancer therapy research, collaborating with industry leaders like CRISPR Therapeutics AG to revolutionize patient care.

NKTX Articles